-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCT-1000 in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCT-1000 in Vulvar Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCT-1000 in Vulvar Cancer Drug Details: SCT-1000 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bis-5 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bis-5 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bis-5 in Small-Cell Lung Cancer Drug Details: Bis5 (LB-1410) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BSI-060T in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BSI-060T in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BSI-060T in Endometrial Cancer Drug Details: BSI-060T is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGN-STNV in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SGN-STNV in Pancreatic Cancer Drug Details: SGN-STNV is under development for the treatment of solid...
-
Product Insights
Cabra Corral
Cabra Corral is a Hydro project located in Salta, Argentina. The project is owned by The AES Corp and was developed by Panedile Argentina SAICF eI. The project came online in 1978. Empower your strategies with our Cabra Corral report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the...
-
Product Insights
Rio Grande
Rio Grande is a Hydro project located in Cordoba, Argentina. The project is owned by Empresa ProvIncial de Energia de Cordoba and was developed by Panedile Argentina SAICF eI. The project came online in 1986. Empower your strategies with our Rio Grande report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
El Tambolar
El Tambolar is a Hydro project located in San Juan, Argentina. The project is owned by Power Construction Corporation of China and is developed by Panedile Argentina SAICF eI; Sinohydro Corp Ltd. The project is currently under construction. Empower your strategies with our El Tambolar report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nofazinlimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nofazinlimab in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nofazinlimab in Hepatocellular Carcinoma Drug Details: Nofazinlimab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PIPE-307 in Multiple Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PIPE-307 in Multiple Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PIPE-307 in Multiple Sclerosis Drug Details:PIPE-307 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sepantronium Bromide in Burkitt Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Sepantronium Bromide in Burkitt Lymphoma Drug Details: Sepantronium bromide is under development for the treatment...